End-of-day quote
Other stock markets
|
||
- | - |
|
2023 | NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
2019 | NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding | CI |
Sales 2024 * | 12TCr 8.69Cr 0 724.28Cr | Sales 2025 * | 14TCr 10Cr 0 875.18Cr | Capitalization | 23TCr 17Cr 0 1.39TCr |
---|---|---|---|---|---|
Net income 2024 * | 2.3TCr 1.67Cr - 138.82Cr | Net income 2025 * | 3TCr 2.17Cr - 181.07Cr | EV / Sales 2024 * | 0.86 x |
Net cash position 2024 * | 13TCr 9.3Cr 0 774.98Cr | Net cash position 2025 * | 15TCr 11Cr 0 920.44Cr | EV / Sales 2025 * | 0.54 x |
P/E ratio 2024 * |
10.6
x | P/E ratio 2025 * |
8.06
x | Employees | - |
Yield 2024 * |
2.54% | Yield 2025 * |
2.54% | Free-Float | 56.96% |
Managers | Title | Age | Since |
---|---|---|---|
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 01/12/01 |
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/00/01 |
Woo-Jae Lim
BRD | Director/Board Member | 45 | 25/21/25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yoon Kim
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/00/01 |
Dong-Jin Choi
BRD | Director/Board Member | 64 | 21/19/21 |
Yang-Soo Kim
CEO | Chief Executive Officer | 54 | 01/12/01 |
1st Jan change | Capi. | |
---|---|---|
-9.01% | 23TCr | |
0.00% | 1.96TCr | |
+12.48% | 1.89TCr | |
+7.90% | 1.14TCr | |
-19.32% | 864.98Cr | |
+15.38% | 744.9Cr | |
+11.66% | 602.61Cr | |
-7.99% | 387.32Cr | |
-19.43% | 371.57Cr |